Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tricyclic antidepressant blood levels.

Z T Marshall1, S B Lippmann

  • 1University of Cincinnati School of Medicine, Ohio.

American Family Physician
|March 1, 1988
PubMed
Summary

Tricyclic antidepressant plasma levels vary greatly between individuals, leading to ineffective treatment or toxicity. Monitoring drug levels can improve patient outcomes in managing depression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Internet-observed suicide attempts.

The Journal of clinical psychiatry·2001
Same author

Electroconvulsive therapy in the acute poststroke period.

The journal of ECT·2001
Same author

ECT for major depression and mania with advanced dementia.

The journal of ECT·2001
Same author

Midazolam attenuates ketamine-induced abnormal perception and thought process but not mood changes.

Canadian journal of anaesthesia = Journal canadien d'anesthesie·2000
Same author

Divalproex-induced alopecia: a case report.

Psychiatric services (Washington, D.C.)·1999
Same author

Perioperative extrapyramidal reactions associated with ondansetron.

Anesthesiology·1999

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Psychiatry

Background:

  • Tricyclic antidepressants (TCAs) are commonly prescribed for depression.
  • Significant inter-individual variability exists in plasma concentrations of TCAs, even at standard doses.

Observation:

  • Some patients exhibit unexpectedly low plasma TCA levels, potentially leading to subtherapeutic effects.
  • Other patients may experience toxic plasma TCA levels, increasing the risk of adverse events.

Findings:

  • Individual variations in TCA plasma levels can be attributed to genetic factors influencing drug metabolism.
  • Drug interactions and patient compliance are also significant contributors to plasma concentration variability.

Implications:

  • Plasma concentration monitoring of TCAs can optimize pharmacologic management for depressed patients.
  • Personalized dosing strategies guided by therapeutic drug monitoring can enhance treatment efficacy and safety.

Related Experiment Videos